- Home
- AAMI vs HROW Comparison
AAMI vs HROW Comparison
Compare AAMI & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- HROW
- Stock Information
- Founded
- AAMI 1980
- HROW 1998
- Country
- AAMI United States
- HROW United States
- Employees
- AAMI N/A
- HROW N/A
- Industry
- AAMI Investment Managers
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- AAMI Finance
- HROW Health Care
- Exchange
- AAMI Nasdaq
- HROW Nasdaq
- Market Cap
- AAMI 1.1B
- HROW 1.1B
- IPO Year
- AAMI N/A
- HROW N/A
- Fundamental
- Price
- AAMI $35.80
- HROW $30.77
- Analyst Decision
- AAMI Hold
- HROW Strong Buy
- Analyst Count
- AAMI 2
- HROW 6
- Target Price
- AAMI $27.00
- HROW $59.00
- AVG Volume (30 Days)
- AAMI 250.6K
- HROW 387.0K
- Earning Date
- AAMI 07-31-2025
- HROW 08-06-2025
- Dividend Yield
- AAMI 0.11%
- HROW N/A
- EPS Growth
- AAMI 46.05
- HROW N/A
- EPS
- AAMI 2.40
- HROW N/A
- Revenue
- AAMI $519,799,999.00
- HROW $212,858,000.00
- Revenue This Year
- AAMI $5.28
- HROW $44.92
- Revenue Next Year
- AAMI $6.24
- HROW $38.12
- P/E Ratio
- AAMI $14.68
- HROW N/A
- Revenue Growth
- AAMI 18.00
- HROW 53.49
- 52 Week Low
- AAMI $21.49
- HROW $20.36
- 52 Week High
- AAMI $35.99
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- HROW 55.61
- Support Level
- AAMI N/A
- HROW $29.71
- Resistance Level
- AAMI N/A
- HROW $32.46
- Average True Range (ATR)
- AAMI 0.00
- HROW 1.34
- MACD
- AAMI 0.00
- HROW -0.20
- Stochastic Oscillator
- AAMI 0.00
- HROW 38.55
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.